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Background. Mammals must sense the amount of sugar available to them and respond appropriately. For many years
attention has focused on intracellular glucose sensing derived from glucose metabolism. Here, we studied the detection of
extracellular glucose concentrations in vivo by invalidating the transduction pathway downstream from the transporter-
detector GLUT2 and measured the physiological impact of this pathway. Methodology/Principal Findings. We produced
mice that ubiquitously express the largest cytoplasmic loop of GLUT2, blocking glucose-mediated gene expression in vitro
without affecting glucose metabolism. Impairment of GLUT2-mediated sugar detection transiently protected transgenic mice
against starvation and streptozotocin-induced diabetes, suggesting that both low- and high-glucose concentrations were not
detected. Transgenic mice favored lipid oxidation, and oral glucose was slowly cleared from blood due to low insulin
production, despite massive urinary glucose excretion. Kidney adaptation was characterized by a lower rate of glucose
reabsorption, whereas pancreatic adaptation was associated with a larger number of small islets. Conclusions/Significance.
Molecular invalidation of sugar sensing in GLUT2-loop transgenic mice changed multiple aspects of glucose homeostasis,
highlighting by a top-down approach, the role of membrane glucose receptors as potential therapeutic targets.
Citation: Stolarczyk E, Le Gall M, Even P, Houllier A, Serradas P, et al (2007) Loss of Sugar Detection by GLUT2 Affects Glucose Homeostasis in
Mice. PLoS ONE 2(12): e1288. doi:10.1371/journal.pone.0001288
INTRODUCTION
Sensing of sugar is a survival mechanism enabling organisms to
know when to constitute and mobilize tissue energy stores. It is
known that glucose homeostasis relies on appropriate detection of
glucose concentration, but glucose-sensing mechanisms remain
poorly understood in mammalian cells. Intracellular glucose is
sensed and the resulting signal relayed by metabolic messengers in
tissues. Glucokinase and mitochondrial oxidative fluxes (ATP/
ADP ratio) are involved in regulation of ATP-sensitive K+
channels controlling insulin secretion and are well-described
glucose sensors in pancreatic ß cells [1–3]. Intracellular glucose
metabolism stimulates sensitive-gene transcription in the liver
[4,5,6]. Intracellular glucose metabolism is a common feature of
mammalian cells and modulation of glucose sensing by metabolic
inhibitors, although potent, is not recommended in vivo as most cell
functions and vital parameters would be affected.
Yeasts detect extracellular sugar concentrations with proteins
located in the external membrane [7], including sugar receptors of
the GPCR family and transporter-detectors of the sugar transporter
family [8]. In adipocytes, the glucose transporter GLUT1 detects
glucose with its C-terminus domain activating the ERK pathway by
a mechanism independent of glucose transport and metabolism [9].
In pancreatic beta cells, investigations have yield conflicting results
concerning the possible role of detector for GLUT2 in glucose-
induced insulin secretion. The group of B. Thorens demonstrated
that in mice GLUT2 participates to the first phase of insulin
secretion [10]. Unexpectedly, Fanconi-Bickel patients bearing
GLUT2 invalidating mutations do not develop overt diabetes [11]
but their insulin secretions were not investigated. This suggests that
GLUT2 is less involved in insulin secretion in human than in mice.
Importantly, the role of GLUT2 in insulin synthesis has not been
fully characterized yet in mice and man.
In hepatic cells, GLUT2 detects glucose and activates a signaling
pathway through its large cytoplasmic loop leading to glucose-
induced transcription, independent of glucose metabolism [12]. The
sodium-glucose transporter homolog SGLT-3, was identified as a
glucosesensor inthe plasma membrane ofenteric neuronstriggering
membrane depolarization [13]. Due to these plasma membrane
detectors, cells can adapt to changes in extracellular sugar
concentrations. The role of glucose detectors in glucose homeostasis
has not been evaluated in vivo. Such a study should provide
information on the importance of the glucose-sensing pathway
triggered by detectors, and help elucidate the role of plasma
membrane therapeutic targets inmodulation of glucosehomeostasis.
GLUT2 is expressed in various tissues involved in glucose
homeostasis; thus, we investigated the physiological significance of
GLUT2 detection of extracellular glucose concentration. GLUT2
is involved in metabolic glucose sensing by mediating bi-
directional glucose transport, adjusting intracellular glucose
concentration. It is also involved in the detection of sugar
abundance at the plasma membrane in vitro [12]. GLUT2 has
been shown to contribute to control of food intake and secretion of
insulin and glucagon in GLUT2-null mice [14,15,16], but
detection of both intracellular and extracellular glucose concen-
trations as well as transport are invalidated in those mice.
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1288We quantified, in vivo, the physiological contribution of extracel-
lular sugar detection independent of changes in glucose metabolism.
For this purpose, we used a molecular tool that blocks glucose-
induced gene expression in vitro, but preserves glucose metabolism
[12]. We generated transgenic mice expressing the GLUT2-loop
domain to prevent the detection of extracellular sugar abundance.
We report here the impact of the loss of extracellular glucose
detection on various aspects of glucose homeostasis.
RESULTS
Generation of GLUT2-loop transgenic mice
We generated transgenic mice expressing the large cytoplasmic
GLUT2 loop to investigate its sugar detection function in vivo.W e
obtained four transgenic mice with various copy numbers of
transgene (Fig. 1A). Mouse ‘W’ had the highest copy number of
transgene, growth failure and urinary glucose loss, but survived at
weaning and did not develop diabetes. Unfortunately, ‘W’ was
sterile. Founder ‘B’ had a high transgene copy number and was
viable but some homozygous did not survive. Heterozygous and
homozygous mice from ‘P’ and ‘G’ founders were viable.
Transgene mRNA was present in all the tissues tested, as
expected from the ubiquitous actin promoter used, but at various
levels (Fig. 1B). Transgene mRNA expression was absent in wild-
type (WT) mice. There was no clear correlation between cDNA
copy number and mRNA levels of the transgene. We detected the
protein coded by the transgene by immunoprecipitation of liver
extracts with a specific antibody raised against the GLUT2
intracellular loop (Fig. 1C).
Thus, we created three lines of transgenic mice expressing
various amounts of the transgene in GLUT2- and non GLUT2-
expressing tissues.
Invalidation of extracellular sugar detection in
GLUT2 expressing tissues
We have previously shown in vitro that the GLUT2 loop blocks
glucose stimulation of sensitive gene transcription. In this study, we
investigated in vivo the role of the GLUT2 loop. For this purpose,
we fed mice with a standard diet, then either fasted the mice for
48h or refed (after fasting) them a glucose-rich diet. We studied
genes stimulated directly by glucose and genes stimulated
indirectly by insulin secreted in response to glucose ingestion
(GLUT2, ChREBP, glucokinase, SREBP-1c). The mRNA coded
for these genes accumulated in the liver of wild-type mice 15h after
they consumed a glucose-rich diet, as expected (Fig. 2A). However,
these mRNAs remained at basal levels in transgenic mice (Fig. 2A),
despite similar food consumption. In vivo expression of the GLUT2
loop, therefore, sets the gene-expression profile in fed transgenic
mice to the level established in fasted wild-type mice.
GLUT2 protein levels in liver membrane were similar in wild-
type and transgenic mice fed a glucose-rich diet for five days
(Fig. 2B). Thus, the phenotype of transgenic mice in which glucose
detection by GLUT2 is impaired is not due to low GLUT2 protein
levels in liver membranes. This feature is related to liver expression
of the transgene inhibiting detection of glucose abundance.
We assessed the specificity of GLUT2-mediated sugar detection,
compared to other GLUTs. For this purpose, we studied tissues that
do not express GLUT2 but other members of the GLUT family. We
detected transgene mRNA in epididymal adipose tissue (not shown),
as in muscle (Fig. 1B). Feeding a glucose-rich diet induced a similar
level of accumulation of FAS, SREBP-1c (Fig. 2C) and ACC
mRNAs (not shown) in epididymal fat pads from wild-type and
GLUT2-loop transgenic mice. These findings show that the
expression of the GLUT2 loop did not affect GLUT4-expressing
tissues and suggest that other glucose-sensing pathways are involved
in these tissues. Moreover, peripheral tissues of transgenic and wild-
type mice had similar insulin sensitivity, as determined by an insulin
tolerance test (Fig. 2D). These findings indicate that the GLUT2
loop did not interfere with peripheral glucose disposal by muscle and
adipose tissues that express GLUT4.
Thus, we produced transgenic mice in which GLUT2-mediated
glucose detection was specifically abolished.
Preference for lipid oxidation
We investigated the adaptation of mice to impaired detection of
glucose abundance by measuring the energy expenditure resulting
from glucose and lipid oxidation (Fig. 3). We determined the time
course of resting metabolic rate and respiratory quotient averaged
at 15-minute intervals in wild-type and transgenic mice (Fig. 3A
and B). Resting metabolism, respiratory quotient, and glucose and
lipid oxidation (Fig. 3C) were similar in wild-type and transgenic
mice before food consumption.
Figure 1. Generation of GLUT2-loop transgenic mice. A: Quantification
of the transgene copy number in genomic DNA from independent lines
of mice (Tg G, P, B and W) to the reference gene Apolipoprotein A1
(ApoA1). B: RT-PCR analysis of transgene and L19 control mRNA levels in
various tissues. C: Immunoprecipitation and immunoblot analysis
showing the presence of GLUT2 loop in liver homogenate from
transgenic mice.
doi:10.1371/journal.pone.0001288.g001
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3.6 mg/g (OGTT) occurred after ten minutes and the peak
response for respiratory quotient occurred after 30 minutes. There
was no significant difference between groups (p=0.269). Accord-
ingly, there were no differences between groups for glucose and
lipid oxidation during oral glucose load. The overall metabolic rate
and overall respiratory quotient (measured by the areas under the
respective curves) were slightly, but not significantly lower
(p=0.178) in transgenic mice than in wild-type mice during oral
glucose load.
Then, we fed mice a test meal of 1g standard laboratory chow
containing sugars and lipids. The difference in the thermogenic
response between the two groups was amplified (Fig. 3). Pre-meal
metabolic rate, respiratory quotient, and glucose and lipid oxidation
were similar in wild-type and GLUT2-loop transgenic mice. The
peak response of the respiratory quotient to the meal was slightly
smaller in amplitude and occurred three hours later in transgenic
mice than in wild-type mice. The overall increase in metabolic rate
during the test meal was significantly larger in GLUT2-loop mice
than in wild-type mice (3.260.3 versus 2.060.2 kJ, p,0.02), but the
increase in respiratory quotient was smaller in transgenic mice than
in wild-type mice (Fig. 3A and B). This phenomenon resulted from a
lower level of post-meal inhibition of lipid oxidation in transgenic
mice than in wild-type mice; post-meal glucose oxidation was not
different between groups (Fig. 3C).
We estimated the basal metabolic rate between 5:00 and 7:30
a.m. at the end of the calorimetry session when the mice were in a
post-absorptive/fasting state. Basal metabolic rate was similar
between groups, but respiratory quotient was slightly lower in
transgenic mice (0.8W) than in wild-type mice (0.84W) (Fig. 3B).
Figure 2. Impairment of extracellular sugar detection in GLUT2-expressing tissues in transgenic mice. Effect of a glucose-rich diet on gene
expression in liver (A) and adipose tissue (C). Transgenic (Tg) and wild-type (WT) mice were fasted for 48 h and refed for 15 h before liver and
epididymal fat pad biopsies. Levels of mRNA were analyzed by real time PCR. Values are presented as means6S.E.M. (n=3 to 5 mice/group).
Statistical differences between refed and fasted mice are indicated by *P,0.05, **P,0.01, and ns non significant. B: GLUT2 protein levels in total
membrane preparations from the liver of mice fed a glucose-rich diet for five days. D: Blood glucose concentrations during an insulin tolerance test in
wild-type and transgenic mice. Values are presented as means6S.E.M (n=8 to 10 mice/group).
doi:10.1371/journal.pone.0001288.g002
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type mice and 70% in transgenic mice.
Thus, GLUT2-loop transgenic mice had lower levels of glucose
oxidation than wild-type mice but higher levels of lipid oxidation.
Attenuated response to low and high glucose levels
We tested the capacity of mice with impaired GLUT2-mediated
sugar sensing to detect sugar deficit. After 48h of fasting, the
glycogen content in liver of wild-type mice was lower than taht of
GLUT2-loop transgenic mice (Fig. 4A). Residual glycogen stores
were larger after fasting in liver, kidney and intestine of transgenic
mice than of wild-type mice (Fig. 4A), possibly resulting from the
slight but constant lower rate of glucose oxidation in fasted
GLUT2-loop transgenic mice (Fig. 3C). This phenomenon
occurred despite normal blood glucose concentration (Fig. 4B),
but was probably associated with higher plasma insulin level in
transgenic mice than in wild-type mice (Fig. 4B). Total body fat
Figure 3. Energy expenditure in mice after impairment of extracellular sugar detection. Progression of resting metabolism rate, respiratory
quotient and calculated oxidation recorded at ten-second intervals in wild-type (WT) and transgenic (Tg) mice. The test meal was given just before
the lights were turned off and the response measured until metabolism rate and respiratory quotient returned to pre-meal levels. The changes in
resting metabolism rate and respiratory quotient were included in the calculation of the changes in glucose (Gox) and lipid (Lox) oxidation.
doi:10.1371/journal.pone.0001288.g003
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(Fig. 4B). This finding may be related to the higher level of fat
oxidation observed in the fasted transgenic mice (Fig. 3C).
Plasma free fatty acids (FFA) levels were high in fasted wild-type
mice, and plasma triglyceride levels were low, as expected
(Fig. 4C). Plasma FFA levels were lower and plasma triglyceride
levels were higher six hours after refeeding (Fig. 4C). We observed
a similar, but attenuated profile for plasma FFA levels in
transgenic mice, but plasma triglyceride levels were not signifi-
cantly different in refed and fasted transgenic mice. Consequently,
the triglyceride content remained high in the liver of fed transgenic
mice (Fig. 4C).
This finding indicates that GLUT2-loop transgenic mice are
more resistant to fasting than wild-type mice and suggests that
transgenic mice do not properly detect sugar deficit.
Injection of streptozotocin (a drug that poisons pancreatic ß-
cells) led to pronounced hyperglycemia. We observed significantly
less pronounced hyperglycemia and glucosuria in transgenic mice
than in wild-type mice (Fig. 4D) the day after drug injection.
However, the protection against streptozotocin-induced diabetes
was transient, as blood and urine glucose levels in the two groups
of mice were the same two days after drug injection (Fig. 4D).
Glucose tolerance and pancreatic functions
Glucose modulates many pancreatic functions. We verified that
the regulation of a subset of glucose-sensitive genes was impaired
in the pancreas of GLUT2-loop transgenic mice (Fig. 5A). In the
pancreas, mRNA of GLUT2 and ChREBP (Fig. 5A) and
glucokinase (not shown) accumulated significantly in wild-type
but not in transgenic mice, 2 h after an oral glucose load. We
observed similar accumulation of ACC mRNA in the two groups
of mice (not shown). These findings suggest that glucose detection
in the pancreas, as measured by the stimulation of target genes, is
altered in transgenic mice. GLUT2 protein levels were similar in
pancreas membrane preparations from wild-type and transgenic
mice fed a glucose-rich diet for five days (Fig. 5B).
Blood glucose concentrations during an oral glucose tolerance
test remained significantly higher in transgenic mice than in wild-
type mice, indicating glucose intolerance (Fig. 5C). This occurred
despite glucose and lipid oxidation having the same kinetics in the
two groups of mice (Fig. 3C). Nevertheless, we observed glucose
intolerance in all three transgenic mouse lines (Fig. 5C). Six hours
after being refed a glucose-rich diet, blood glucose concentrations
were similar in the two groups of mice (Fig. 5C). This indicates
that after a delay transgenic mice can regulate blood glucose
concentration similarly to wild-type mice.
Plasma insulin levels during the glucose load remained signif-
icantlylower inGLUT2-loop transgenicmicethaninwild-typemice
(Fig. 5D). Thus, a defective insulin response to oral glucose may
explain, at least in part, glucose intolerance. Pancreatic insulin
content was 30% lower in transgenic mice than in wild-type mice six
hours after being refed a glucose-rich diet (Fig. 5D). Impairment of
glucose detection by GLUT2 in the pancreas attenuated changes in
insulin production in response to glucose or to diet.
Insulin production is regulated by glucose at various steps.
Proinsulin mRNA accumulation was 2.960.5 times higher in wild-
type and 2.360.3 times higher (p=0.3) in transgenic mice fed a
high-glucose diet for two hours than in fasted control mice. These
findings together with the lower insulin protein content in
pancreas of transgenic mice suggest that a GLUT2-mediated
glucose detection step is involved in the translation or maturation
of insulin.
We therefore analyzed the morphology of pancreatic islets.
Immunohistochemical and morphometrical analyses showed that
total islet number/mm
2 of transgenic mice was not different from
that of wild-type mice (Fig. 5E). However, the proportion of
insulin-labeled cells organized as small islets (,25 mm) was higher
in pancreas of GLUT2-loop transgenic mice than of wild-type
mice (p=0.03) (Fig. 5E). This finding is consistent with the lower
pancreatic insulin content in GLUT2-loop transgenic mice than in
wild-type mice six hours after being refed (Fig. 5D).
The invalidation of GLUT2-mediated glucose detection in
pancreatic ß-cells impaired insulin production, but did not modify
GLUT2 protein level and insulin mRNA accumulation. Though
islet morphology appeared preserved, insulin-positive cell organi-
zation was altered in transgenic mice.
Excretion of excess glucose by the kidney
Besides the insulin action on peripheral tissues, excess glucose is
efficiently cleared from blood by renal excretion. We thus
analyzed the role of GLUT2-mediated extracellular glucose
detection in kidney of transgenic mice.
We verified that GLUT2-mediated sugar detection was impaired
in kidney of transgenic mice. Unlike in wild-type mice, consumption
of a glucose-rich diet after 48 h of fasting did not lead to
accumulation of GLUT2 and SREBP-1c mRNAs in transgenic
mice (Fig. 6A and not shown). Basal levels of these mRNAs were not
different in kidney of wild-type and transgenic mice and the GLUT2
protein levels in membrane preparations from wild-type and
transgenic mice were the same (Fig. 6B). The lack of glucose-
stimulated gene expression confirmed that kidney of transgenic mice
did not properly detect extracellular glucose concentration.
We assessed the consequences of impaired GLUT2-mediated
glucose detection in the kidney by examining kidney structure by
echography. The kidneys of transgenic mice were 160% larger in
diameter than wild-type kidneys (Fig. 6C), although they had
similar weights. We observed a difference in echogenicity due to
glycogen but not to water accumulation in transgenic kidney
(Fig. 6C and 3A).
The ratio of urine volume excreted to the water volume
consumed per day was identical in the two groups (not shown). We
analyzed the urine composition and found that the measured
parameters did not differ between the two groups if mice were fed
a standard diet (Table 1). In contrast, the consumption of a
glucose-rich diet led to significantly greater urine glucose loss in
GLUT2-loop transgenic mice than in wild-type mice (Table 1).
We used an oral glucose load to document this specific loss of
glucose in the urine. The transgenic mice lost substantially more
glucose in the urine than wild-type mice did (Fig. 6D). Moreover,
we detected glucose in the urine of wild-type mice when the blood
glucose concentration reached 200610mg/dl, whereas glucosuria
appeared as soon as the blood glucose concentration reached
17064mg/dl in transgenic mice (p,0.03) (Fig. 6D). This indicates
a lower glucose threshold in transgenic mice than in wild-type
mice. We observed a significantly lower SGLT1 mRNA level in
transgenic mice than in wild-type mice 15 hours after being refed,
whereas SGLT2 mRNA levels were similar in the two groups.
These findings suggest that impairment of glucose detection
provoked major adaptation in glucose renal reabsorption.
DISCUSSION
In this study, we show that prevention of sugar detection strongly
affects many mechanisms involved in glucose homeostasis.
Transgenic mice excreted massive amount of glucose in urine,
which protected them against excess glucose despite attenuated
pancreatic insulin production and a preference for lipid oxidation
over glucose oxidation. The GLUT2 loop, used here as a molecular
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1288Figure 4. Detection of low and high glucose levels. A: Left panel: glycogen content in liver, kidney and intestine from fasting wild-type (WT) and
transgenic (Tg) mice. Values are presented as means6S.E.M. (for the liver n=6 to 7 mice per group, for the kidney and intestine n=3 mice/group).
Statistical differences between transgenic and wild-type mice are indicated as *P,0.05. Right panel: Representative pancreas sections from fed wild-
type and transgenic mice stained with PAS reagent. The black bar corresponds to 50 mm. B: Fasting metabolic parameters. Blood glucose
concentration, plasma insulin concentration and total fat are indicated for wild-type and transgenic mice after fasting for 48 h. Values are presented
as means6S.E.M. (n=4 mice/group). Statistical differences between transgenic and wild-type mice are indicated as *P,0.05 and ns non significant.
Right panel: Example of a DEXA scan. C: Lipid metabolism. Plasma free-fatty acids (FFA) and triglyceride concentrations in wild-type and transgenic
mice in the fasting state or 6h after refeeding. Values are presented as means6S.E.M. (n=3 to 5 mice/group). Statistical differences between refed
and fasted mice are indicated as ***P,0.001, *P,0.05 and ns non significant. Right panel: Liver triglyceride content in liver extract from wild-type and
transgenic mice 6h after refeeding. Values are presented as means6S.E.M. (n=4 to 5 mice/group). Statistical differences between transgenic and
wild-type mice are indicated as **P,0.01. D: Blood glucose and urine glucose levels measured after steptozotocin injection. Values are presented as
means6S.E.M. (n=3 to 4 mice/group). Statistical differences between wild-type (open squares) and transgenic (closed triangles) mice are indicated as
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0001288.g004
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1288Figure 5. Pancreatic function in mice after impairment of extracellular sugar detection. A: Effect of a glucose-rich diet on gene expression in the
pancreas of wild-type (WT) and transgenic (Tg) mice fasted for 48h and refed for 15 h. Levels of mRNA were analyzed by real-time PCR. Values are
presented as means6S.E.M. (n=3 to 4 mice/group). Statistical differences between refed and fasted mice are indicated as **P,0.01 and ns non
significant. B: GLUT2 protein levels in total membrane preparations of pancreas from mice fed a glucose-rich diet for five days. C: Left panel: Blood
glucose concentrations during an oral glucose tolerance test in wild-type and transgenic mice fasted for 24 h (n=17 for wild-type mice, n=2 to 5 for
transgenic mice). Statistical differences between transgenic and wild-type mice are indicated as ***P,0.001, *P,0.05 and ns non significant (two-way
ANOVA) for the areas under the curves. Right panel: Blood glucose concentrations in wild-type and transgenic mice in the fasted state or 6 h after
being refed with a glucose-rich diet. Values are presented as means6S.E.M. (n=4 to 8 mice/group). D: Upper panel: Plasma insulin concentrations
during an oral glucose tolerance test in fasted wild-type and transgenic mice (n=10 to 13 mice/group). Statistical differences between transgenic and
wild-type mice are indicated as ***P,0.001 (two-way ANOVA) for the areas under the curves. Lower panel: Pancreatic insulin content in mice 6h after
being refed a standard diet. Values are presented as means6S.E.M. (n=5 mice/group). Statistical differences between transgenic and wild-type mice
are indicated as *P,0.05. E: Upper panel : Representative immunostaining with antibody against insulin of pancreatic sections from wild-type and
transgenic mice. Arrows indicate small islets. The bar corresponds to 100 mm. Lower panel: Histomorphometric comparisons of islet number, size and
ß-cell mass. Proportion of small islets (,25 mm) to total number of islets is statistically different indicated as *P,0.03 between transgenic and wild-
type mice.
doi:10.1371/journal.pone.0001288.g005
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1288Figure 6. Kidney function in mice after impairment of extracellular sugar detection. A: Effect of a glucose-rich diet on gene expression in the
kidney of transgenic (Tg) and wild-type (WT) mice fasted for 48 h and refed for 15 h. Levels of mRNA were analyzed by real-time PCR. Values are
presented as means6S.E.M. (n=3 to 4 mice/group). Statistical differences between refed and fasted mice are indicated as *P,0.05, **P,0.01 and ns
non significant. B: GLUT2 protein levels in total membrane preparations of kidney from mice fed with a glucose-rich diet for five days. C: Structure,
size and weight of kidneys from wild-type and transgenic mice shown by ultrasonic image (transverse cross section). D: Urine and blood glucose
concentrations during an oral glucose tolerance test in fasted wild-type and transgenic mice (n=3 mice per group). Statistical differences between
transgenic and wild-type mice are indicated as **P,0.01 (two-way ANOVA) for the areas under the curves. E: Levels of SGLT mRNA were analyzed by
real-time PCR. Values are presented as means6S.E.M. (n=3 to 4 mice/group). Statistical differences between refed and fasted mice are indicated as
**P,0.01 and ns non significant.
doi:10.1371/journal.pone.0001288.g006
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affecting basal mRNA levels in liver, kidney and pancreas. On the
other hand, the GLUT2-null mice, in which both sugar entry and
sugar detection are invalidated, deteriorates after weaning, and mice
die probably because they are unable to handle excess glucose by
appropriate insulin secretion [10,15]. The phenotype of GLUT2-
loop transgenic mice may be related to the maintenance of glucose-
and insulin-sensitive functions at basal levels.
The expression of the GLUT2-loop transgene interfered with
GLUT2-triggered glucose detection. This highlights the efficiency
of this plasma membrane chemoreceptor for glucose, and provides
a new therapeutic target for glucose homeostasis. Consumption of
a glucose-rich diet still led to accumulation of target gene mRNA
in adipose tissue. Indeed, hyperglycemia-modulated gene expres-
sion has been reported in peripheral tissues [17]. In tissues without
GLUT2, glucose detection occurred by GLUT2-independent
mechanisms, probably due to ‘‘intracellular’’ metabolism. As
expected, these mechanisms were not directly affected by the
molecular tool (GLUT2 loop). Accordingly, GLUT2-loop trans-
genic mice had normal insulin sensitivity in peripheral tissues,
mainly muscle and adipose tissue. The capacity of peripheral
tissues to respond to insulin remained unaffected by the expression
of the transgene.
The amount of GLUT2 protein in the membranes of liver,
pancreas and kidney cells showed that the phenotype of transgenic
mice was not caused by defective glucose entry into the cells but
rather by the inability of the cells to detect extracellular glucose.
A fundamental characteristic of GLUT2-loop transgenic mice
was that basal metabolism remained unaffected. Nevertheless, in
transgenic mice fed with the usual diet, thermic response occurred
but was two times slower than in wild-type mice. Fuel oxidation
indicated that transgenic mice utilize more lipids than wild-type
mice. Better lipid oxidation improves resistance to high fat feeding
[18] and increases weight and fat losses without major changes in
lean body mass [19], a feature observed in these transgenic mice.
Wild-type mice use their energy stores during fasting whereas
transgenic mice protect their energy stores when deprived of food
due to an impaired ability to detect changes in glucose levels. The
slower mobilization of glycogen stores in transgenic compared to
control mice is probably due to plasma insulin, which remained
high during fasting, and to the preference for lipid oxidation over
glucose oxidation. Partial preservation of energy stores in
transgenic mice occurred despite similar levels of circulating
glucose, suggesting that low glucose concentration was inade-
quately detected in these mice.
Transient protection against streptozotocin-induced diabetes has
been observed possibly due to many GLUT2-mediated effects,
including drug access to pancreatic ß cells [20], but not to
accelerated urinary glucose loss or larger stores of pancreatic insulin.
Therefore, we concluded that GLUT2-expressing tissues
involved in glucose homeostasis poorly detected both high and
low glucose levels.
Pancreatic adaptations to impaired detection of
extracellular glucose
Pancreatic glucose sensing is mediated by metabolism and
primarily by glucokinase activity [3]. How glucokinase activity is
translated into a quantitative signal remains unknown. It has been
reported that after being metabolized in the ß-cell, glucose
stimulates insulin gene transcription by a mechanism involving
SREBP-1c [21]. Insulin mRNA accumulated in transgenic mice
after consumption of a glucose-rich diet as in control mice. Thus,
GLUT2-mediated glucose sensing did not significantly alter
transcription and stability of insulin mRNA. Nevertheless,
transgenic pancreas had low insulin content, consistent with
reports showing that insulin expression is also regulated by glucose
at a translational level. Fasted mice had lower islet insulin mRNA
content as compared to fed mice [22]. While in vitro the acute
changes in glucose affected mainly insulin translation
[23,24,25,26], chronic changes in glucose impacted on both
insulin gene transcription [27] and mRNA stability [28]. In ß-cell,
long term glucose sets the preproinsulin mRNA level whereas
short term glucose regulates the translation rates of proinsulin
biosynthesis [25,26,21].
Decreased insulin content in pancreas of transgenic mice may
thus result from small ß-cell mass and increased number of small
islets compared to controls. Supporting this idea, pancreatic ß-cell
expansion is induced by glucose-stimulated proliferation [29–32],
and glucose-mediated reduction of apoptosis [33,34]. However,
glucotoxicity has been linked to persistent hyperglycemia in type II
diabetes as a result of impaired ß-cell proliferation [35,36] and
increased apoptosis [37]. Plasma insulin concentration did not
increase adequately in response to a glucose load in GLUT2-loop
transgenic mice suggesting that GLUT2-mediated glucose detec-
tion is necessary for normal ß-cell development and function. A
reduced b cell mass has also been reported in mice, lacking insulin
receptors in pancreatic b-cells [38], and in HGFR KO mice [39],
suggesting that there are many regulators of pancreatic ß cell mass
[40]. Some of these regulators may be under the control of
Table 1. Urinary excretion in mice after impairment of extracellular sugar detection. Metabolic and electrolyte levels in 24-h
urine samples from wild-type (WT) or transgenic mice fed a standard or a glucose-rich diet. Values are presented as means6S.E.M.
(n=6 per group). Statistical differences between wild-type and transgenic mice are indicated as *P,0.05 ns non significant, nd
indicates not determined.
..................................................................................................................................................
Standard diet Glucose-rich diet
Parameters Wild-type Transgenic P Wild-type Transgenic P
Glucose (g/mmol creatinine) 0.03360.007 0.02360.004 ns 0.01660.005 0.06760.021 *
K (mmol/mmol creatinine) 25622 3 62n s 1 5 621 3 62n s
Cl (mmol/mmol creatinine) 98671 1 0 68n s 1 0 8 689 9 610 ns
Ca (mmol/mmol creatinine) 1.960.4 3.160.8 ns 0.660.1 1.860.6 ns
Na (mmol/mmol creatinin) 42654 6 66 ns n.d. n.d.
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broader analysis, is necessary to resolve this question.
Kidney adaptations to impaired detection of
extracellular glucose
The urinary excretion of glucose observed here might be due to
specific or general tubular adaptations. In the kidney, a failure of
tubules to reabsorb small molecules will cause increased urinary
excretion of glucose but also of amino acids, minerals, electrolytes
(sodium, potassium, bicarbonate) and water as observed in renal
Fanconi syndrome [41]. This will result in polyuria, polydipsia,
dehydration, hypophosphatemic rickets and growth retardation.
Similarly, patients affected by GLUT2 mutation do not reabsorb
glucose and various filtered solutes because of impairment in
GLUT2-mediated efflux of glucose [42]. Accumulation of
glycogen in renal tubular cells has been described in Fanconi-
Bickel patients [11]. Glycogen deposit is maintained in the kidney
of fasted GLUT2-loop transgenic mice but there was no
perturbation of basal kidney function. Such perturbation appeared
only after oral glucose load or the consumption of a glucose-rich
diet. In GLUT2-loop transgenic mice, normal reabsorption of
glucose and associated solutes occurred when blood glucose levels
were under 170 mg/dl. Glucose reabsorption is not sufficient in
transgenic mice and the threshold is lower than in wild-type mice,
but there was no significant electrolyte loss. The renal adaptations
related to GLUT2-mediated sugar detection are restricted here to
decreased glucose reabsorption. We found a relationship in kidney
between glucose detection by GLUT2 and the decrease in SGLT1
mRNA. Mutations in SGLT1 gene provokes glucose-galactose
malabsorption accompanied by mild glucosuria whereas familial
renal glucosuria is due to mutations in the SGLT2 gene [43].
Several proteins of proximal tubule and their regulators are likely
to be involved in the process of glucose tubular reabsorption.
Thus, further investigation is required to understand the molecular
mechanisms for this renal functional adaptation.
The mouse phenotype described here, characterized by a low
level of insulin secretion and a high level of glucosuria, is
reminiscent of a monogenic (HNF1a) form of diabetes. MODY3
patients have a defect in insulin secretion but no obvious
hyperglycemia probably related to massive urinary glucose loss
[44]. The maximal renal reabsorption capacity of these patients, as
in HNF1a-null mice, is decreased due to substantially less
transcription of a sodium/glucose co-transporter (SGLT2) [45].
In contrast with GLUT2-loop transgenic mice, HNF1a-null mice
had defective renal tubular reabsorption of various metabolites
(amino acids, phosphates), in addition to glucose, suggesting that
HNF1a levels are not involved in the defect we report in mice with
an impaired detection of extracellular glucose.
In conclusion, artificial inhibition of GLUT2-mediated sugar
sensing in a limited number of tissues, modified various parameters
of glucose homeostasis. This may be advantageous because urinary
glucose loss can eliminate excess glucose and reduce fat deposits.
Moreover, an attenuated secretion of insulin on demand can
preserve pancreatic potential in the long term.
MATERIALS AND METHODS
Creation of transgenic mice
The actin promoter was used to drive strong and ubiquitous
expression of the transgene. We used pCAGGS-IRES2-EGFP
(kindly provided by MR Hirsh), derived from the pCAGGS
eukaryotic expression vector [46]. We replaced the internal
ribosome entry site (IRES) and the enhanced green fluorescent
protein (EGFP) gene with the EGFP-Loop DNA fragment coding
for amino acids 237 to 301 previously described [12].
Genotyping of transgenic mice was carried out by PCR with a
forward primer recognizing EGFP (59-CGAATTCCTGTCCA-
GAAAGCC-39) and a reverse primer recognizing the GLUT2
loop (59-AGAAGTCAGATGCTCAAGGGG-39). The transgene
copy number was determined by real-time PCR with the same
primers. Apolipoprotein A1 was used as a reference (primers from
A. Kalopissis).
The animals were bred in the transgenic animal facilities of
IFR58 (Paris). All animal procedures complied with published
recommendations for the use of laboratory animals by the French
government. Tg B , Tg P and Tg G indicate transgenic mice from
the B, P and G lines, respectively.
Analysis of metabolic parameters
Blood samples were collected from the tail of conscious mice.
Blood glucose concentrations were measured with a glucometer
(Accu-chek Go, Roche); urinary glucose, with test strips (Keto-
Diastix, Bayer); plasma insulin concentrations, with an ELISA kit
with a mouse insulin standard (Rat/Mouse insulin Kit, LINCO);
plasma free fatty acids (FFA) concentrations, with an NEFA C
determination kit (Wako); plasma triglycerides, with a TG
enzymatic determination kit (Biome ´rieux) and tissue glucose
content, with a D-glucose/D-fructose determination kit (Boehrin-
ger Mannheim/R-Biopharm, Roche).
Levels of urine proteins, creatinine, sodium, potassium,
chloride, calcium, phosphate and glucose were measured with
an automatic analyzer (Hitachi 911; Boehringer Mannheim).
Tissue glycogen content was measured enzymatically (Roche
Applied Science). Before insulin content determination, the
pancreas was homogenized in an acid-alcohol solution.
RNA extraction and quantitative PCR analyses
Total RNA from liver, kidney, pancreas and epididymal fat pads
was extracted with Tri-Reagent (MRC). Reverse transcription
(RT) was carried out with 1 mg total RNA. Messenger RNA was
quantified with the Light-Cycler system (Roche Molecular
Biochemicals I primer, Indianapolis). Specific primers were
designed for GLUT2 (Fwd: 59-ACCCTGTTCCTAACCGGG-
39, Rev: 59-TGAACCAAGGGATTGGACC-39), proinsulin (Fwd:
59-AAACCCACCCAGGCTTTTGT-39, Rev: 59-ATCCACAA-
TGCCACGCTTCT-39) SGLT1 (Fwd: 59-GGGTGGCTTTG-
AATGGAA-39, Rev: 59-CCTTGATGTAAATCGGGACAA-39)
and SGLT2 (Fwd: 59-GCTGGATTTGAGTGGAATGC-39,
Rev: 59-CGGTCAGATACACTGGCACA-39). Primers used to
detect glucokinase, SREBP-1c and ChREBP [47], FAS and ACC
[48] have been described previously. L19 was used as an internal
control [49].
Immunoblotting analysis and immunoprecipitation
Crude membrane preparations were obtained as previously
described [50]. The membrane proteins were resolved by 12%
SDS-PAGE and transferred to nitrocellulose membrane.
Membrane proteins were analyzed by immunoblotting with
antibody against the GLUT2 intracellular loop (produced by
Eurogentec) and the first GLUT2 extracellular loop (Chemicon).
For immunoprecipitation, frozen liver was homogenized in RIPA
buffer (20 mM Tris pH7.5, 1 mM, EDTA, 0.15M NaC1, 10 mM
KC1, 1%NP-40, 0.1% deoxycholate, 0.1% SDS) containing
protease inhibitor cocktail (Roche) and 42 mM MG132 (Calbio-
chem).Liverextractswereincubated withrabbitpolyclonalantibody
against the GLUT2 intracellular loop and protein G-Sepharose
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with the antibody against the GLUT2 loop.
Immunohistochemical and morphometric analyses
The pancreas was fixed overnight in Bouin’s solution and
embedded in paraffin according to standard procedures. Ten
sections per pancreas, taken every 72
nd serial section (6 mm thick)
obtained throughout the block of pancreas, were immunostained
for insulin (guinea pig anti-porcine insulin antibody, 1:500,
ImmunO, MP biomedical), detected with a peroxidase-conjugated
rabbit anti-guinea pig antibody (1:50, Dako) and a peroxidase
substrate kit (DAB, Vector Laboratories). Tissue sections were
counterstained with hematoxylin. Morphometrical analyses were
performed as described in [51]. Surface area occupied by insulin
staining and total pancreatic tissue were quantified with a 106
objective on a Leica microscope outfitted with a camera and the
Leica Qwin software (Leica, France). The 1-cell fraction (percent
beta-cell in the pancreas) represents the ratio of insulin-positive cell
area to the total pancreatic tissue area on the entire section. 1-cell
mass was calculated as the surface ratio between 1-cell and total
pancreatictissuemultipliedbypancreaticweight.The proportionsof
small (,25 mm), medium (.26 to ,100mm), and large (.100mm)
islets were also quantified. A total of 250-500 islets were counted per
pancreas. At least 3 mice were analyzed per group.
Histological sections of pancreas were incubated with Schiff
reagent (Merck) for glycogen visualization.
In vivo studies
Mice were fed either a standard carbohydrate diet (23% proteins,
51% carbohydrates, 3% lipids) obtained from Dietex (Saint-
Gratien, France) or a glucose-rich diet (19% casein, 0.3%
methionine, 65% dextrose) as previously described [52].
For oral glucose tolerance tests (OGTT), mice were fasted for
24 h and then received a glucose load of 3.6 g/kg. For insulin
tolerance tests (ITT), mice were injected intraperitoneally with
1unit/kg insulin (Actrapid Novo).
When required, mice were injected with 200 mg/kg strepto-
zotocin (Sigma).
For urine analysis, mice were individually housed in metabolic
cages with free access to water and a standard or glucose-rich diet.
The mice were allowed to adapt to the cages for three days. Intake
of food and water was then measured every 24 h and urine was
collected throughout three consecutive days. Spontaneously
excreted urine from each 24 h-period was collected for measure-
ment of urinary creatinine and protein excretion.
Indirect calorimetry
These studies were conducted in an open-circuit, indirect
calorimetric device [53,54]. The apparatus was improved and
developed within the framework of the AddenFi project, for the
valorization and commercialization of laboratory setups, at INRA-
AgroParisTech, INA-PG UMR 914 Research Unit [53]. The
temperature in the metabolic cage was maintained at 3261uC.
Oxygen consumption and carbon dioxide production were
recorded every 10 s using a computer-assisted data acquisition
program written under Labview 7.1. A previously described
stoichiometric formula was used to calculate oxidation of glucose
and lipid. Protein oxidation was not taken into account. Resting
and activity-related metabolic rates were calculated separately
(Kalman filtering method) [53,54,55].
The mice were placed in the metabolic cage at 9:00 a.m. with
water, but no food, available. An oral glucose tolerance test
(3.6 mg/g) was carried out at 2:00 p.m. and a calibrated test meal
(1g of the standard diet) was given at 6:00 p.m. Respiratory
exchanges and spontaneous activity were continuously recorded
until 9:00 a.m. the following day.
The basal metabolic rate was defined as the mean resting
metabolic rate measured between 5:00 a.m. and 7:30 a.m. when
the mice were in a post-absorptive state. The changes in metabolic
rate, respiratory quotient, glucose and lipid oxidations induced by
the OGTT and test meal were calculated relative to the stable pre-
test values measured during the preceding hour.
Total fat
Total fat was determined by dual-energy X-ray absorptiometry
(Lunar PIXImus mouse densitometer; GE LUNAR Corp.). Mice
were fasted for 48h before the analysis and anesthetized with
Avertin (0.02 ml/g body weight).
Kidney echography
Ultrasonic images were acquired in vivo using a clinical
dermatological imaging system (Ultrasons Technologies, Tours,
France) with custom modifications for dynamic data acquisition
and high-frequency electronics [56]. Mice were anesthetized with
1.5% isoflurane.
Statistical analyses
Results are presented as means6S.E.M., and unpaired t test was
used for data analysis unless indicated (i.e. ANOVA) (GraphPad
Software).
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